SLE treatment with type 1 interferon antagonists in the era of COVID-19
In view of recent clinical trials, which patients with SLE may benefit most from treatment with a type 1 interferon antagonist? Is the safety profile of this therapy acceptable today, in the era of the mutating SARS-CoV-2 pandemic?